OEM and private label are defined by who holds the drawings, not who holds

A 2 mL clear glass vial from two suppliers can pass the same dimensional stack, fit the same autosampler, and still behave differently at puncture 47: one septum cores at the third injection on a 23-gauge needle and the other runs clean to 120. When that happens on a validated method, the first question the lab manager asks is whether the two vials came from the same factory. Sometimes yes. Sometimes no. The OEM vs private label aijiren difference is not a marketing distinction; it is a question about who holds the drawings, who owns the mold, and who signs the certificate of analysis when the lot drifts. I have sat on both sides of that conversation, as the private-label buyer and as the OEM supplier, and the gap between the two arrangements is wider than most procurement teams assume.

This article is about the mechanics of that gap. It is not about pricing structure or contract terms; those are covered elsewhere. It is about tooling ownership, recipe control, and what changes in the physical product and its documentation when the brand on the box changes but the factory does not. If you already know what an HPLC vial is and you are trying to decide whether to buy OEM or private label, or to audit a supplier who claims one when they are doing the other, this is the layer that matters.

OEM and private label are defined by who holds the drawings, not who holds the box

In the consumables trade, “OEM” and “private label” get used loosely. I have seen both terms applied to the same shipment depending on which side of the deal you stand on. The only definition that survives an audit is this: an OEM arrangement exists when the buyer supplies the specification, the drawings, and the acceptance criteria, and the factory builds to them. A private label arrangement exists when the factory supplies the specification and the buyer applies a brand to a product the factory already makes. Everything else, including price, MOQ, and lead time, follows from that distinction.

That sounds academic until you are holding a certificate of analysis. Under OEM, the CoA reports against your limits, because you wrote them. Under private label, the CoA reports against the factory’s standard limits, which may be looser than yours and which you did not negotiate. I have seen a private-label buyer discover, six months into a supply agreement, that the “9 mm screw thread” on their branded vial was a nominal callout with no thread gauge in the factory’s incoming inspection. The product met the factory’s spec. It did not meet the buyer’s, because the buyer never wrote one.

The three documents that actually define the arrangement

When I audit a supplier relationship, I ask for three things before I ask about price. They tell me more about who controls the product than any brochure:

• The drawing. A controlled drawing with a revision number, tolerances on every critical dimension (neck OD, thread pitch, crimp bead diameter, septum thickness, bore), and a title block naming the drawing owner. If the drawing owner is the factory, you are buying private label regardless of what the contract says.
• The specification. The document that lists which dimensions are inspected, at what frequency, with what gauge, and against what acceptance limit. Under OEM, you sign this. Under private label, the factory signs it and you accept it.
• The change-control clause. The mechanism by which the factory must notify you before changing resin lot, mold, or annealing cycle. Under OEM this is a contractual obligation with a notice period. Under private label it is often a courtesy, or absent.

If a supplier cannot produce all three on request, the arrangement is private label in substance even if the invoice says OEM. I have walked into factories that print “OEM” on the quotation letterhead and then hand over a generic catalog drawing with no revision block. That is a private-label relationship with better branding.

Tooling ownership decides who can change the product without telling you

This is the part most procurement teams miss. The mold is the product. A 9 mm screw-thread vial neck is formed by a split cavity mold with a specific thread core; the crimp bead on an 11 mm crimp vial is formed by a specific bead insert. If you own the tooling, or if the tooling was built to your drawing and paid for by you, the factory cannot change the mold geometry without your sign-off. If the factory owns the tooling, they can re-cut a cavity, swap a thread insert, or move production to a sister plant, and your product changes underneath you.

I have seen this play out with a crimp vial where the buyer had been running the same part number for three years. The factory retired a mold insert and replaced it with a new one cut to the same nominal drawing but with a 0.08 mm difference in the crimp bead diameter. The buyer’s crimper, set for the old bead, started producing seals that passed a leak test at the factory but failed a 24-hour gravimetric check in the lab. The factory had not violated any agreement, because the agreement did not name the tooling. The buyer had been buying private label for three years and calling it OEM.

What tooling ownership buys you in practice

When you own the tooling, three things become possible that are not possible otherwise:

• Dimensional hold across mold life. You can require the factory to re-qualify the mold at defined shot counts and report capability (Cpk) on the critical dimensions. A neck OD held to ±0.10 mm at first article and ±0.15 mm at end of mold life is a spec you can write only if you own the tool.
• Resin lock. You can name the resin grade and the supplier, and require lot traceability back to the incoming certificate. Private-label buyers get whatever resin the factory bought that quarter.
• Annealing and stress-relief control. Glass vials need a defined annealing cycle to relieve forming stress; a poorly annealed vial can crack at the crimp or shed glass particles into the sample. Under OEM you can specify the lehr temperature profile and require a stress test (polariscope inspection) on each lot. Under private label you inherit the factory’s cycle, which may vary by line.

The tooling question also determines what happens when the brand changes. If you move your brand to a new factory, you do not move the product unless you move the tooling with it. This is why some private-label buyers find that switching suppliers mid-method forces a revalidation: the new factory’s mold, resin, and annealing cycle produce a vial that meets the same nominal drawing but not the same functional behavior. The dimensional stack may pass while the puncture count drops from 90 to 60. That is a tooling and process difference, not a specification difference, and it is invisible on a datasheet.

The recipe is the part of the product you cannot see on a drawing

Even with identical tooling and identical drawings, two factories can produce different vials. The difference is the recipe: the glass batch composition, the forming temperature, the annealing profile, the septum compound, the lamination thickness, the washing and drying sequence, and the packaging environment. Under OEM, you can control some of these and audit the rest. Under private label, you get the factory’s standard recipe, which may be excellent but which you cannot verify and cannot change.

I treat the recipe as the higher-risk half of the OEM vs private label question, because tooling differences show up in dimensional inspection and recipe differences often do not. A vial can be dimensionally perfect and still fail on extractables, on crimp seal integrity, or on particle shedding, and none of those failures will appear on a caliper check.

Where recipe control actually shows up in the data

The places I look for recipe drift, and the numbers that flag it:

• Septum compression set. A silicone/PTFE septum that has been cured to a different recipe will show different compression set after 24 hours at 70 °C. If the factory changed compound supplier, the set value can move by 5 to 10 percentage points, which changes reseal behavior after the first puncture.
• Extractable profile. The washing and drying sequence after molding determines residual organics on the glass surface. A change from a three-stage to a two-stage wash can raise the extractable count in a blank injection by a factor of two or three.
• Particle count. The packaging environment (cleanroom class, bag material, nitrogen purge) sets the particle load on the vial at the point of use. A move from an ISO Class 8 to an uncontrolled pack-out area changes the count by an order of magnitude.

Under OEM, these are auditable parameters with acceptance limits you wrote. Under private label, they are the factory’s internal process, and your only visibility is the finished-product CoA, which may not report them at all. This is why I tell buyers that the OEM vs private label aijiren difference is really a question about how much of the process you can see. If you can see the recipe, you can hold it. If you cannot, you are buying a black box with a brand on it.

What changes when the brand changes but the factory does not

Here is the scenario that trips up the most procurement teams. You are buying private label from a factory. You decide to switch to OEM with the same factory, or you decide to move your brand to a different factory that makes a similar product. In both cases the brand changes. In one case the factory does not. The product may still change, and the reason is instructive.

When you move from private label to OEM with the same factory, the physical product may not change at all on day one. What changes is the documentation, the change-control obligation, and your ability to specify. The factory now builds to your drawing and your acceptance limits. The first lot under the new arrangement may be identical to the last private-label lot, because the factory is still running the same mold and recipe. The difference shows up at the first process change: under OEM you get notice, under private label you do not.

When you move your brand to a different factory, the product changes even if the drawing is the same, because the tooling and recipe are different. This is where I have seen labs forced into revalidation. A method validated on a private-label vial from factory A, then re-sourced to factory B under the same brand, can show a shift in peak area RSD from 0.8% to 1.9% on the same standard, driven by a different septum bleed profile. The method still passes, but the trend is visible on a control chart, and the lab spends a month chasing a ghost.

The field cases that make this concrete

Case one: the crimp that passed at the factory and failed in the lab. A pharmaceutical QC lab was running a private-label 11 mm crimp vial. The factory’s leak test, a 30-second pressure hold, passed every lot. The lab’s own test, a 24-hour gravimetric check at 40 °C, started showing weight loss above 0.5 mg/day on about one vial in twenty. The measurement that identified the cause was a crimp bead diameter check on the failing vials: 7.92 mm against a nominal 8.00 mm, a 0.08 mm shortfall that let the crimper bottom out before the seal seated. The factory had changed a bead insert three months earlier without notifying the buyer, because the buyer did not own the tooling. The fix was to move to an OEM arrangement with the bead diameter on the buyer’s drawing and a first-article inspection on every insert change. The failure rate dropped to zero over the next four lots.

Case two: the septum that cored at puncture 47. An environmental lab running EPA SW-846 methods on a private-label 9 mm screw vial saw coring on a 23-gauge needle at around injection 40 to 50, well short of the 100-puncture rating on the datasheet. The measurement that identified the cause was a septum thickness check across the lot: the factory’s standard septum ran 1.30 mm nominal but the lot averaged 1.18 mm, because the factory had switched to a thinner compound to reduce cost. The thinner septum cored earlier because the needle had less material to push aside before the bore punched through. The fix was an OEM specification naming the septum thickness at 1.30 mm ± 0.05 mm and requiring a puncture test to 100 on each lot. The lab now runs to 120 punctures on the same needle with no coring.

Both cases share a structure: the factory changed something inside its own process, the buyer had no visibility, and the failure showed up only in the lab’s functional test, not in the factory’s inspection. That is the private-label failure mode. The OEM arrangement does not prevent process changes; it makes them visible before they reach the lab.

Decision checklist: which arrangement fits your method

The choice is not about prestige. It is about how much of the product’s behavior your method depends on, and how much visibility you need to hold it. The table below is the one I use with buyers when they are deciding whether to move a part from private label to OEM.

If more than three rows land in the OEM column, the private-label arrangement is a latent failure. If most land in the private-label column, OEM is overkill and you are paying for visibility you will not use. The mistake I see most often is a lab running a validated method on a private-label vial because the unit price looked better, then spending the savings several times over on a revalidation after a process change they never saw coming.

How to verify which arrangement you are actually in

Do not take the supplier’s word for it. The arrangement is defined by documents and by the physical product, and both can be checked. Here is the sequence I run, in order, when a buyer asks me to confirm whether their “OEM” supplier is really OEM:

1. Ask for the controlled drawing and check the title block. If the drawing owner is the factory, stop. You are private label. If the drawing owner is you or your contract manufacturer, continue.
2. Ask for the first-article inspection report. An OEM relationship has one, dated, with the critical dimensions measured on the first parts off the tool. A private-label relationship usually does not.
3. Ask for the change-control procedure. Specifically, ask what triggers a notification and what the notice period is. If the answer is “we will let you know,” there is no procedure.
4. Ask for capability data on the critical dimensions. A Cpk on neck OD and crimp bead diameter over the last 20 lots tells you whether the process is in control. If the factory cannot produce it, they are not measuring it.
5. Run a functional test on the incoming lot. Puncture to 100 on your needle gauge, gravimetric seal check at your method temperature, and a blank injection for extractables. The functional test is the only check that catches recipe drift the drawing cannot see.

I also cross-check the physical product against the documentation. If the drawing says 1.30 mm septum and the lot measures 1.18 mm, the arrangement is private label in practice regardless of the paperwork. The caliper does not lie. This is the same discipline I apply when I audit incoming glass and resin, and it is the reason I keep a set of go/no-go gauges on the bench rather than trusting the CoA alone.

Where the brand sits in a regulated method

One more piece of the OEM vs private label aijiren difference that buyers underestimate: under a validated method, the brand on the vial is part of the method’s documented materials. If you change brands, you change a method input, and under USP <621> and the ISO 17025 scope, that change may require a documented assessment. The OEM arrangement does not exempt you from that, but it makes the assessment tractable, because you can show that the drawing, tooling, and recipe did not change even though the brand did. Under private label, a brand change is a product change, and you have no documentation to prove otherwise.

This is why I recommend that labs running regulated methods treat the OEM arrangement as the default and private label as the exception, justified by volume or by a non-critical application. The cost of OEM is real, in tooling, first-article inspection, and the engineering time to write the drawing. The cost of private label is deferred, and it shows up as a revalidation, a failed lot, or a control chart that will not settle. I know which cost I would rather budget for.

For buyers who want to see how this plays out across the product line, the Aijiren catalog and the specification pages at Vials With Caps and Vial Supplier show the drawing-level detail that separates an OEM part from a private-label one. For method context, the U.S. EPA SW-846 test methods and the technical resources at Restek are useful references when you are writing acceptance limits, and the consumables documentation from Agilent and Thermo Fisher shows how the major instrument makers specify the vial-to-autosampler interface. For the chromatography side of the same question, Lab Chromatography covers the method-level consequences.

The decision rule is simple. If your method depends on the vial’s behavior at puncture 50 or on a seal that holds for 24 hours, buy OEM and own the drawing, the tooling, and the change-control clause. If your method tolerates the factory’s standard recipe and you can absorb a silent process change without revalidating, private label is a legitimate choice. The failure mode is not choosing one or the other; it is buying private label while believing you bought OEM, and discovering the difference at the first lot that drifts.

References & further reading

Related resources from our lab consumables network:

• Aijiren at aijirentech.com
• Vials With Caps at vialswithcaps.com
• Vial Supplier at vialsupplier.com
• Lab Chromatography at labchromatography.com

External references and standards:

• Agilent chromatography consumables and columns
• Thermo Fisher chromatography and sample handling
• U.S. EPA SW-846 test methods for waste and materials
• Restek technical resources for chromatography